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Abstract :  Acute myeloid leukemia (AML) is characterized by an increase in the number of 
myeloid cells in the marrow and an arrest in their maturation. Various genetic mutations are 
associated with AML. FMS-like tyrosine kinase 3 (FLT3), a member of the class III receptor 
tyrosine kinase family, plays an important role in stem cell survival, and the development of 
dendritic and natural killer cells. FLT3/TKD mutations are generally missense mutations or in-
frame alterations of residues D835 and I836 within the activation loop of the FLT3 protein. D835 
mutations have been reported to occur in ≈ 7% of AML patients. Mutations have also been 
reported  in exon 4 of isocitrate dehydrogenase 1 (IDH1) in ≈9% of AML patients. Mutations in 
FLT3/TKD and IDH1 genes were studied in AML patients from Pakistan and correlated with the 
laboratory findings. FLT3/TKD mutations were found in 7%, while IDH1 mutations were found in 
10% Pakistani AML patients. Neither of these mutations was significantly correlated with age 
and sex, although the incidence of these mutations was higher in female patients. These 
mutations were found to be positively associated with each other. IDH1 mutations were 
positively associated with FAB type M1 and negatively associated with FAB type M2. In 
conclusion, the overall incidence of all these mutations in Pakistani patients was within the 
globally reported ranges. 
 
Key words:  AML, acute myeloid leukemia, FLT3/TKD mutations, IDH1 mutations, WBC 
Count. 
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INTRODUCTION 
 
Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid 
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic 
insufficiency (granulocytopenia, thrombocytopenia, or anemia), with or without leukocytosis.  
FMS-like tyrosine kinase 3 (FLT3), also known as stem cell tyrosine kinase-1 (STK1) or 
fetal liver tyrosine kinase-2 (FLK-2), is a member of class III tyrosine kinase (TK) receptors. It 
includes five immunoglobulin-like loops in the extracellular region, a transmembrane region, an 
intracellular juxta-membrane (JM) domain, two tyrosine kinase (TK) domains interrupted by a 
kinase insert and a C-terminal tail (Agnes et al., 1994). The gene is located at chromosome 13q12 
and consists of 24 exons (Rosnet et al., 1991; Abu-Duhier et al., 2001a). 
The expression of FLT3 is found mainly in hematopoietic stem cells in the bone marrow, 
lymph nodes and thymus (Rosnet et al., 1993), but is also seen in other tissues including 
cerebellum, placenta, gonads, and brain   (Maroc et al., 1993). After the ligand binds, the 
receptor dimerizes and autophosphorylates, which activates downstream signalling pathways, 
resulting in the proliferation of pluripotent stem cells (Lyman, 1995). Other cytokines such as Kit 
ligand also influence this interaction. In fact, FLT3 ligand or KIT ligand alone induce very little 
proliferation of in vitro human progenitor cells. But, when used together, they have a synergistic 
effect on stem cell proliferation (Hannum et al., 1994). 
The FLT3 gene is expressed in 93% of AML, 100% of B cell ALL and 87% of T-cell ALL 
patients (Drexler, 1996). In AML, over expression of FLT3 mRNA has been reported in many 
studies, suggesting that this high level of expression may have some critical role in increased 
proliferation and survival of the leukemic cells (Carow et al., 1996). Two types of mutations have 
been reported in the FLT3 gene in AML patients viz., internal tandem duplications (FLT3/ITD) and 
mutations in the second tyrosine kinase domain (FLT3/TKD). FLT3/ITDs result from the 
duplication and tandem insertion of a portion of the juxtamembrane (JM) region. The duplicated 
region is always present between exons 14 and 15 of the FLT3 gene (Nakao et al., 1996). The 
FLT3/ITDs are always in frame and produce functional FLT3 protein. FLT3/ITDs are one of the 
most frequent mutations reported in AML, found in 13 to 32% of adult AML patients (Gale, 
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2003), and are associated with worse prognosis. FLT3/TKD mutations in exon 20 include at least 
six different substitutions within the D835 codon, predominantly tyrosine and histidine, less 
frequently valine, glutamate and asparagine. The deletion of I836 and insertion of nucleotides 
have also been detected, but the sequence always remains in frame. The incidence of these 
mutations varies between 5% and 7% in adult AML patients (1, 2). The impact of FLT3/TKD 
mutations on prognosis is unclear. 
Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative 
decarboxylation of isocitrate, producing alpha-ketoglutarate and carbon dioxide in the citric acid 
cycle. Three IDHs have been reported: one NAD(+)-dependent IDH, which is cytosolic, and two 
NADP(+)-dependent IDHs, one of which is mitochondrial and the other cytosolic. Each NADP(+)-
dependent isozyme is a homodimer. The IDH1 gene is on chromosome 2 at 2q33.3 and consists 
of 30.12kb. It encodes one of the NADP(+)-dependent isocitrate dehydrogenases, which is found 
in the cytoplasm and peroxisomes. It plays a significant role in cytoplasmic NADPH production.  
 Point mutations in the exon 4 (R132) of the IDH1 gene were first reported in 12% cases 
of glioma (3). Similar IDH1 mutations were also found in more than 70% of the WHO grade I and 
III astrocytomas and in glioblastomas. These mutations have also been identified in 9% of 
primary AML patients, and are more associated with normal karyotype AML (16%) (Mardis et al., 
2009). In a study on de novo AML adult patients, 10% patients with normal karyotype were 
found to have IDH1 R132 mutations. These mutations were found to be associated with isolated 
trisomy 8, NPM1 mutations and FAB subtype M1 (Chou et al., 2010). 
 
 In the present study, FLT3/TKD and IDH1 mutations were studied in 70 AML patients 
from Pakistan and correlated with hematological findings. 
 
 
 
MATERIALS AND METHODS 
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Subjects 
Samples from 70 Pakistani AML patients were included in this study. The AML patients 
were selected according to standard hematological and clinical parameters with the help of 
consultant hematologists at different hospitals in Lahore, Pakistan from January 2006 to 
February 2009. Clinical and laboratory findings were obtained on a prescribed proforma from 
the hospital. DNA was extracted from all the samples using the Guanidine Thiocyanate and 
ethanol precipitation method (Malferrari et al., 2002). DNA concentrations were measured on a 
NanoDrop ND-1000 spectrophotometer and each DNA sample was diluted to a final working 
concentration of 30ng/µl with TE buffer for further use in PCR. 
 
PCR amplification 
For the screening of FLT3/TKD mutations, PCR was used to amplify a 278 base pair 
fragment covering FLT3 exon 20. For IDH1 mutations screening, a 369 base pair fragment 
covering IDH1 exon 4 was amplified. For both FLT3/TKD and IDH1, the PCR mixture contained 1X 
Optimase buffer, 1.5mM MgSO4, 0.2mM dNTPs, 0.5mM each primer (17F2 and 17R3 for 
FLT3/TKD, 4F and 4R for IDH1, Table 1), 0.5 units Optimase polymerase (Transgenomic Limited, 
Glasgow, UK) and 30ng DNA in a total reaction volume of 20 µl. Cycling conditions for PCR were: 
Initial denaturation at 95°C for 5 minutes and then 35 cycles each of 95°C for 30 seconds, 60°C 
for 30 seconds and 72°C for 30 seconds, followed by a final extension at 72°C for 5 minutes. A 
known wild type and mutant-positive sample were also amplified along with patient samples. 
Five micro liters of each PCR product were run on a 2% agarose gel in 1X TBE buffer to confirm 
the presence of PCR product. To enhance the formation of heteroduplexes before running on 
DHPLC, the PCR products were denatured at 95°C for 4 min and then allowed to cool down 
slowly to room temperature at a rate of 1°C/min.  
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DHPLC running conditions 
Flow rate of mobile phase was 0.9 mL/min. The gradient of buffer A and B contained 
55% buffer B at the beginning with an increase of 2% per minute to 63% at the end. The duration 
of the gradient was 4 minutes. The temperature of the column oven was 59.0°C for FLT3/TKD 
and 57.0°C and 59.0°C for IDH1. Volume of PCR product per injection was 5µl. The ultraviolet 
detector was set at 260 nm. Heterozygous profiles were identified visually on the basis of the 
appearance of additional earlier peaks of eluting DNA on the chromatograms. Homozygous 
samples showed only one peak. The relative mutant level was visually assessed using the height 
of the mutant peak compared with that of wild type peak of the same sample run. 
 
Confirmation of FLT3/TKD mutations by EcoRV digestion and sequencing 
The samples which showed an additional peak on the DHPLC chromatogram were PCR 
amplified and digested with EcoRV. The PCR mixture contained 1X Bioline buffer, 1.0mM MgCl2, 
0.2mM dNTPs, 0.5mM each primer (17F2 and 17R3), 0.5 units Taq polymerase (Bioline, London, 
UK) and 30ng DNA. The total reaction volume was 20 µl. Cycling conditions for PCR were: 35 
cycles each of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds, followed by a 
final extension at 72°C for 5 minutes. A known wild type and mutant-positive sample were also 
amplified along with unknown samples. The PCR products were run on a 2% agarose gel. Five 
micro liters of each PCR product were digested with EcoRV (New England BioLabs, Hitchin, UK). 
The digestion mixture contained 20 units EcoRV, 1X NEB buffer 3 and 1µg BSA. The final volume 
was adjusted to 10µl and placed at 37°C for 4-5 hours. The digested products were run on a 2% 
agarose gel. The wild type fragments were digested into two fragments of 187bp and 91bp in 
size while the mutant products remained uncut at 278bp. The PCR products generated using 
Bioline reagents were cleaned up using QIAquick PCR purification kit as per manufacturer’s 
protocol and were sent to an in-house sequencing service. 
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Confirmation of IDH1 p.R132 mutations by restriction digestion 
For R132H mutations, amplicons of 200bp were generated using Bioline PCR with 
primers IDH1ex4/F2 and IDH1/R132H/MM(R) (Table 1). The PCR mixture contained 1X Bioline 
buffer, 1.0mM MgCl2, 0.2mM dNTPs, 0.5mM each primer, 0.5 units Taq polymerase (Bioline, 
London, UK) and 30ng DNA. The total reaction volume was 20 µl. Cycling conditions for PCR 
were: 35 cycles each of 95°C for 30 seconds, 64°C for 30 seconds and 72°C for 30 seconds, 
followed by a final extension at 72°C for 5 minutes.  PCR products were digested with BspHI 
(New England BioLabs, Hitchin, UK) using manufacturer’s recommendations. The digested 
products were run on a 2% agarose gel. Wild-type (WT) amplicons were uncut (200bp) and 
R132H-positive amplicons were reduced to 168bp.  
For R132C, R132S and R132L mutations, amplicons of 199bp were generated using 
Bioline PCR with primers IDH1ex4/F2 and IDH1/R132C/MM(R) (Table 1). The PCR mixture 
contained 1X Bioline buffer, 1.0mM MgCl2, 0.2mM dNTPs, 0.5mM each primer, 0.5 units Taq 
polymerase (Bioline, London, UK) and 30ng DNA. The total reaction volume was 20 µl. Cycling 
conditions for PCR were: 35 cycles each of 95°C for 30 seconds, 64°C for 30 seconds and 72°C for 
30 seconds, followed by a final extension at 72°C for 5 minutes. PCR products were digested with 
TaqI (New England BioLabs, Hitchin, UK) using manufacturer’s recommendations. The digested 
products were run on a 2% agarose gel. WT amplicons were reduced to 168bp but amplicons 
carrying an R132C, R132S or R132S mutation remained uncut (199bp). All the IDH1 mutations 
were also confirmed by sequencing.  
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RESULTS 
 
AML patients 
Out of these 70 patients, 38 were male and 32 were female. Median values and range of 
age, WBC count, platelet count and %blasts for males and females along with FAB types are 
shown in Table II.  
There was no difference in the median values for WBC count (P = .38), platelet count (P = .26) 
and % blasts (P = .13) of the male and female patients. Median age of male patients was 
significantly higher than that of female patients (P = .03). There was no patient with either M0 or 
M7 FAB type. FAB type M2 had the maximum number of patients followed by M1 and M4. 
Relatively smaller number of patients was seen in M3, M5 and M6 (Table II).  
 
Frequency of mutations 
FLT3/TKD mutations were detected in 5 patients (7%) while IDH1 mutations were 
detected in 7 patients (10%). The incidence of FLT3/TKD mutation was almost equal among male 
(8%) and female (6%) patients (P = .95) while that of IDH1 mutations was higher in male (13%) 
than female (6%) patients but this was not statistically significant (P = .34, Table III). The overall 
incidence of both the mutations was slightly higher in male (21%) than in the female (12.5%) 
patients but this was not significant (P = .42). 
FLT3/TKD mutations were found to be equally distributed among all age groups (P =.66). 
A significantly higher incidence of the IDH1 mutation was seen in elderly patients (>50 years of 
age, P = .02). Neither of the mutations was significantly associated with sex, any specific FAB 
type, WBC count, platelet count or blast percentage.  
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FLT3/TKD mutations 
In the 5 FLT3/TKD mutant-positive cases, D835Y was the most common FLT3/TKD 
mutation, found in 4 samples as a sole mutation, accounting for 80% of the mutant-positive 
patients and 6% of the total cohort. The fifth patient had three different mutations with 
different levels; D835H being high, R834R intermediate and D835Y being low (Figs. 1 and 3). The 
restriction digestion results confirmed the DHPLC results (Figs. 1 and 2). 
 
IDH1 mutations 
 In the 7 IDH1 mutant-positive cases, 3 different types of mutations were detected. 
R132C and R132H were detected at the same frequency (3 in 7, 43%). R132S mutation was seen 
in one case. The DHPLC results (Fig. 4) were confirmed by restriction digestion (Fig. 5) and 
sequencing (Fig. 6). 
 
 
DISCUSSION 
 In this study, the mutations in FLT3/TKD and IDH1 (exon 4) genes were studied in AML 
patients of Pakistan. The association of these mutations with each other and with clinical 
characteristics of the patients was also studied.  
 The male to female ratio in Pakistani AML patients was 1.2:1.0 (56% male, 45% female) 
which was in accordance with US National Cancer Institute statistics about Asian populations. 
 
FLT3/TKD mutations   
 Developing appropriate molecular biology techniques to detect different molecular 
abnormalities in human malignancies is a major challenge. Even in AML alone, there are many 
different reported genetic mutations. Information derived from the detection of some of these 
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mutations is important for clinical management of the disease. Low level mutations can be very 
difficult to detect using conventional mutation detection techniques. It is necessary therefore to 
use sensitive and high throughput techniques that are capable of detecting these mutations. 
 Using DHPLC, FLT3/TKD mutations were detected in 7% of the Pakistani cohort. There 
are a number of advantages in using DHPLC over the standard EcoRV restriction enzyme 
digestion method that has been used in the majority of previous studies. Firstly, it is more 
sensitive. In the current study, there was one case which was EcoRV negative but DHPLC 
positive. The EcoRV-digested PCR product was therefore used as the template in a fresh 
FLT3/TKD PCR. When the product was digested with EcoRV, a mutant band was prominent on 
the gel. This suggests that the mutation level in that patient was very low. In addition, 
interpretation of EcoRV digestion greatly depends on the efficiency of the restriction digest. In 
some cases, it was extremely difficult to differentiate between an undigested low level mutant 
and the incomplete digestion of FLT3/WT. Using DHPLC however, such low level mutants were 
detected efficiently. This observation highlights the sensitivity of the DHPLC technique for the 
detection of mutations that are present in a small proportion of the amplified alleles. Another 
major limitation of restriction digestion screening is that it detects mutations only within a very 
specific region of DNA, usually 4-6 base pairs. Although the most frequent FLT3/TKD mutations 
occur within codons 835 and 836 and disrupt the EcoRV digestion site, a number of mutations 
occur outside this region. The DHPLC technique, on the other hand, detects mutations across a 
wider region of DNA. Furthermore, the chromatogram profile produced by different mutations 
was found to be highly specific and reproducible, in most cases enabling direct mutation 
identification from the WAVE pattern without the need for sequencing (Figure 1 and 4). 
Considering the clinical management of AML patients with FLT3/TKD mutations, there are clear 
advantages to the use of DHPLC. 
In the current cohort, a D835 mutation was seen in 4 cases as a sole mutation. 
Interestingly, one of the mutant positive patients had three different mutations; D835H, D835Y 
and R834R. Presence of more than one mutation has already been reported (Yamamoto et al., 
2001). The EcoRV digested PCR product was used as a template for re-amplification of the PCR 
product for sequencing in that case.   
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 FLT3/TKD mutations were not associated with age or sex. This was in accordance with 
other studies (Yamamoto et al., 2001; Mead et al., 2007). The mutations were not found to be 
associated with any of the FAB types. Some studies have shown a positive correlation of the 
mutations with FAB type M5 (Thiede et al., 2002; Bacher et al. 2008) and a negative correlation 
with FAB types M2 and M6 (8) while others have shown no association with any of the FAB types 
(Mead et al., 2007; Whitman et al., 2008).  
 
IDH1 mutations 
 Acquired mutations in the IDH1 gene have been identified in 8% (Mardis et al., 2009) 
and 5.5% (Chou et al., 2010) of newly diagnosed AML cases. In the current study, IDH1 
mutations were seen in 10% (Pakistani samples) of AML patients. R132C and R132H compete for 
being the most frequent IDH1 mutations in AML (Mardis et al., 2009; Abbas et al., 2010). In 
present study, R132C and R132H were detected at the same frequency (3 in 7, 43%). The 
mutations were found to be positively associated with higher age (P = 0.02, Table 3). No 
association of the mutations with sex or FAB types was seen.  
The overall frequency of the FLT3/TKD and IDH1 mutations in this study was higher than 
most of the other studies. The most likely reason for this is the use of DHPLC, which is a more 
sensitive technique than other conventional mutation detection techniques. 
 
Coincidence of FLT3/TKD and IDH1 mutations with other described mutations 
 Using DHPLC, we have previously reported the frequency of NPM1 mutations and 
FLT3/ITD mutations in the Pakistani AML patients (Ali et al., 2013a,b).  Table IV shows the 
coincidence of FLT3/TKD mutations with the previously described FLT3/ITD and NPM1 
mutations. The percentage of FLT3/TKD mutations in FLT3/ITD and NPM1 mutant-positive 
patients was not much different from that of the wild type patients. No FLT3/TKD mutation was 
seen in IDH1 mutant-positive patients. No significant association was seen between FLT3/TKD 
mutation and any of the other three mutations. 
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Table V shows the coincidence of IDH1 mutations with previously reported FLT3/ITD and 
NPM1 mutations in the acute myeloid leukemia patients of Pakistan. Although no IDH1 mutation 
was seen in FLT3/ITD mutant-positive patients, this was not statistically significant (P = .11). 
Same was the case with FLT3/TKD mutant-positive patients (P = .29). Incidence of the IDH1 
mutations in mutant-positive patients was almost equal to that of the wild type patients (P = 
.83). So, IDH1 mutations were not found to be significantly associated with any of the three 
mutations. 
 
 
CONCLUSIONS 
 
Mutations in FLT3/TKD and IDH1 genes were studied in AML patients from Pakistan and 
correlated with the laboratory findings. FLT3/TKD mutations were found in 7%, while IDH1 
mutations were found in 10% Pakistani AML patients. Neither of these HPLC mutations was 
significantly correlated with age and sex, although the incidence of these mutations was higher 
in female patients. These mutations were found t be positively associated with each other. IDH1 
mutations were positively associated with FAB type M1 and negatively associated with FAB type 
M2. In conclusion, the overall incidence of these mutations in Pakistani patients was within the 
globally reported ranges. 
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FIGURE LEGENDS 
Fig. 1. Wave (DHPLC) pattern of samples with (a) wild type FLT3/TKD, (b) a D835Y mutation 
and (c) D835H, R834R and D835Y mutations  
Fig. 2. A representative gel demonstrating FLT3/TKD mutations using EcoRV restriction 
enzyme digestion. Lane 1 contains undigested PCR product. Lanes 2 and 3 contain 
EcoRV-digested mutant-negative and mutant-positive controls respectively. Lanes 4 
and 8 show complete digestion of the PCR product, indicative of absence of the 
mutation in these samples. Lanes 5, 6 and 7 show the presence of mutant and wild 
type bands, indicative of mutant-positive samples. 
Fig.3. Sequencing chromatogram showing FLT3/TKD mutations. (a) D835Y (G→T) mutation 
and (b) three different mutations in one patient, namely D835H (G→C) being high, 
R834R (A→G) intermediate and D835Y (G→T) being low. The arrows indicate the 
mutations. 
Fig. 4.  Wave (DHPLC) patterns of samples with different IDH1 mutations. 
Fig. 5.  Representative gels showing mutant-specific restriction enzyme digestion of IDH1 
mutations.  
(a) BspHI restriction digestion for R132H mutations: Lane 1, wild type amplicons are 
uncut (200bp);  Lanes 2-6 contain R132H mutant-positive amplicons which are 
reduced to 168bp after restriction digestion. 
(b) TaqI restriction digestion for R132C, S or L mutations: Lane 1, undigested PCR     
product;  Lanes 2 and 4, wild type amplicons are reduced to 168 bp after restriction 
digestion; Lanes 3, 5 and 6, amplicons carrying R132C, R132S and R132L remain 
uncut (199bp)  
Fig. 6. Sequencing chromatograms showing different IDH1 mutations. The arrows indicate the 
mutations.  
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Table I. Oligonucleotide primers used for mutation screening      
 
Gene/Exon Primer Sequence 
WT Product 
Size (bp) 
FLT3/20 
17F2:  5’-CATCACCGGTACCTCCTACTG-3’ 
278 
17R3:  5’-TAACGACACAACACAAAATAGCCGT-3’ 
IDH1/4 
4F:    5’-CATTTGTCTGAAAAACTTTGCTTC-3’ 
369 
4R:    5’-ACATGCAAAATCACATTATTGCCA-3’ 
IDH1/4 
4F2:   5’-ATCACTCCTGATGAGAAGAGGGTTGAG-3’ 
200 
R132H/MM(R): 5’-ACATGACTTACTTGATCCCCATAAGCATCA-3’ 
R132C/MM(R): 5’-CATGACTTACTTGATCCCCATAAGCATGTC-3’ 199 
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Table II. Patient characteristics (Median and range) of all patients, male and female patients. 
 
 Total (n=70) Male (n=38) Female (n=32) 
Age (Years)    
Median 30 32 24 
Range 9-68 16-68 9-50 
WBC count (x109 per litre)    
Median 26 24 32 
Range 0.8-196 0.8-141 1.2-196 
Platelet count (x109 per litre)    
Median 64 53 76 
Range 7-322 7-187 12-322 
% Blasts    
Median 42 48 41.5 
Range 15-98 15-98 18-82 
FAB Types    
M0 0 0 0 
M1 18 11 7 
M2 24 13 11 
M3 4 2 2 
M4 9 5 4 
M5 7 2 5 
M6 3 2 1 
M7 0 0 0 
Unknown 5 3 2 
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Table III.  Demographic characteristics according to the FLT3/TKD and IDH1 mutations 
 
 Total 
FLT3/TKD IDH1 
WT MT (%) P % MT WT MT (%) P % MT 
Sex          
Male 38 35 3 (60) 
.79 
8 33 5 (71) 
.34 
13 
Female 32 30 2 (40) 6 30 2 (29) 6 
Age (Years)          
<25 30 27 (41) 3 (60) 
.66 
10% 28 (44) 2 (29) 
.02 
7 
26-50 36 34 (52) 2 (40) 6% 33 (52) 3 (43) 8 
>50 4 4 (6) 0 (0) 0% 2 (3) 2 (29) 50 
FAB Types          
M1 18 17 (26) 1 (20) .76 6% 15 (24) 3 (43) .27 17% 
M2 24 22 (34) 2 (40) .78 8% 22 (35) 2 (29) .74 8% 
M3 4 4 (6) 0 (0) .43 0% 4 (6) 0 (0) .35 0% 
M4 9 8 (12) 1 (20) .62 11% 9 (14) 0 (0) .15 0% 
M5 7 7 (11) 0 (0) .29 0% 6 (10) 1 (14) .69 14% 
M6 3 3 (5) 0 (0) .50 0% 3 (5) 0 (0) .42 0% 
Unknown 5 4 (6) 1 (20)  20% 4 (6) 1 (14)  20% 
WBC count x109/L          
<10 24 23 (35) 1 (20) 
.87 
4% 24 (38) 0 (0) 
.22 
0% 
10-50 19 17 (26) 2 (40) 11% 17 (27) 2 (29) 11% 
51-100 13 12 (18) 1 (20) 8% 10 (16) 3 (43) 23% 
>100 9 8 (12) 1 (20) 11% 8 (13) 1 (14) 11% 
Unknown 5 5 (8) 0 (0)  0% 4 (6) 1 (14)  20% 
Platelet count x109/L          
01-50 25 23 (35) 2 (40) .25 8% 24 (38) 1 (14) .37 4% 
19 
 
51-100 21 18 (28) 3 (60) 14% 19 (30) 2 (29) 10% 
>100 18 18 (28) 0 (0) 0% 15 (24) 3 (43) 17% 
Unknown 6 6 (9) 0 (0)  0% 5 (8) 1 (14)  17% 
% Blasts          
01-50 39 36 (55) 3 (60) 
.81 
8% 37 (59) 2 (29) 
.29 
5% 
51-100 26 24 (37) 2 (40) 8% 22 (35) 4 (57) 15% 
Unknown 5 5 (8) 0 (0)  0% 4 (6) 1 (14)  20% 
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Table IV. Coincidence of  FLT3/TKD mutations with previously reported  FLT3/ITD and 
NPM1 mutations in acute myeloid leukemia patients  of Pakistan.  
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Table V. Coincidence of  IDH1 mutations with previously reported  FLT3/ITD and NPM1 
mutations in acute myeloid leukemia patients  of Pakistan.  
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Fig. 1. Wave (DHPLC) pattern of samples with (a) wild type FLT3/TKD, (b) a D835Y mutation 
and (c) D835H, R834R and D835Y mutations   
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Fig. 2. A representative gel demonstrating FLT3/TKD mutations using EcoRV restriction 
enzyme digestion. Lane 1 contains undigested PCR product. Lanes 2 and 3 contain 
EcoRV-digested mutant-negative and mutant-positive controls respectively. Lanes 4 
and 8 show complete digestion of the PCR product, indicative of absence of the 
mutation in these samples. Lanes 5, 6 and 7 show the presence of mutant and wild 
type bands, indicative of mutant-positive samples. 
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Fig.3. Sequencing chromatogram showing FLT3/TKD mutations. (a) D835Y (G→T) mutation 
and (b) three different mutations in one patient, namely D835H (G→C) being high, 
R834R (A→G) intermediate and D835Y (G→T) being low. The arrows indicate the 
mutations. 
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Fig. 4.  Wave (DHPLC) patterns of samples with different IDH1 mutations. 
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(a) (b) 
 
 
 
Fig. 5.  Representative gels showing mutant-specific restriction enzyme digestion of IDH1 
mutations.  
(a) BspHI restriction digestion for R132H mutations: Lane 1, wild type amplicons are 
uncut (200bp);  Lanes 2-6 contain R132H mutant-positive amplicons which are 
reduced to 168bp after restriction digestion. 
(b) TaqI restriction digestion for R132C, S or L mutations: Lane 1, undigested PCR     
product;  Lanes 2 and 4, wild type amplicons are reduced to 168 bp after restriction 
digestion; Lanes 3, 5 and 6, amplicons carrying R132C, R132S and R132L remain 
uncut (199bp).  
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Fig. 6. Sequencing chromatograms showing different IDH1 mutations. The arrows indicate the 
mutations.  
 
 
